Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides

Journal of Urology

Volumn 166, Issue 2, 2001, Pages 461-469

  Lebedeva, Irina ^b   Raffo, Anthony ^b   Rando, Robert ^b   Ojwang, Joshua ^b   Cossum, Paul ^b   Stein, C A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE

Author keywords

Antisense; Bladder; Bladder neoplasms; Oligonucleotides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOTOXIC AGENT; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN BCL X;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CARCINOMA CELL; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0034934161     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65964-2     Document Type: Article

References (26)

1. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
2. Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity
3. Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels
4. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells
5. Bcl-2 and p53 expressions in invasive bladder cancers
6. Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder
7. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer
8. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer
9. Expression of bcl-2 and bcl-X in bladder cancer
10. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
11. Variable levels of bcl-2, bcl-x and bax mRNA in bladder cancer progression
12. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers
13. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression
14. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines
15. Cationic porphyrins: Novel delivery vehicles for antisense oligodeoxynucleotides
16. Is irrelevant cleavage the price of antisense efficacy?
17. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli
18. Physicochemical properties of phosphorothioate oligodeoxynucleotides
19. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
20. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides
21. Antisense oligonucleotides in cancer: Recent advances
22. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides
23. RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: Use of backbone modification to improve specificity
24. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures
25. Kinetic characteristics of Escherichia coli RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes
26. Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80 S ribosome